UNSPSC 51385902: Tianafac

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C11H9ClO2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P0T3ZRK3XV, chemically known as benzo(b)thiophene-2-acetic acid, 5-chloro-3-methyl- but generally known as tianafac, which bears US NIH Compound Identifier 68686. European Medicines Agency schedules Tianafac in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11006MIG. The term TIANAFAC is an International Non-Proprietary Name.

UNSPSC 51385902 Tianafac (Commodity) covers the procurement of pharmaceutical products and related health-supply items by state and local government entities, including naloxone, drug deactivation systems, and generic multi-source pharmaceuticals for distribution through public health agencies, state health departments, and cooperative purchasing vehicles. State and local buyers under this code range from county health departments and state health and human services commissions to multistate cooperative purchasing alliances that aggregate demand across multiple jurisdictions and serve hospital systems, community health facilities, and public health programs.

Recent activity shows issuing bodies across different organizational tiers and geographies. Seminole County, Florida issued IFB 60459723LAS in June 2026 for annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries to its Community Health Building in Sanford, with a response deadline of July 26, 2026. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather market intelligence on vendors' capacity to support direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products for distribution across participating state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026. Vendors responding to MMCAP must maintain contractual relationships with at least two of three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson) and comply with cGMP and Drug Supply Chain Security Act certification. Recent procurement activity concentrates in the Southeast and Midwest, with Texas, Florida, Minnesota, and Oregon showing documented opportunities.